Company news
Arbutus Biopharma Corporation (NASDAQ:ABUS) news
Every Arbutus Biopharma Corporation press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Arbutus Biopharma : Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share
August 24, 2026
Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share
August 24, 2026
Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
August 21, 2026
Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 12, 2026
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
July 16, 2026
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 13, 2026
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
April 15, 2026
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
March 23, 2026
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
March 3, 2026
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 13, 2025
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
October 7, 2025
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 6, 2025
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
June 25, 2025
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 14, 2025
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
May 7, 2025
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
April 23, 2025
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
March 27, 2025
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
March 3, 2025
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
February 25, 2025
Arbutus Provides 2025 Corporate and Financial Update
January 13, 2025
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
November 26, 2024
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
November 15, 2024
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
November 15, 2024
Arbutus to Present at Jefferies London Healthcare Conference
November 14, 2024
Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 6, 2024
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
October 23, 2024
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
October 15, 2024
Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
October 1, 2024
Arbutus to Participate in Two Upcoming Investor Conferences
September 3, 2024
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 1, 2024
Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
July 18, 2024
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
June 6, 2024
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
June 6, 2024
Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
June 5, 2024
Arbutus to Participate in Jefferies Global Healthcare Conference
May 29, 2024
Arbutus to Present Imdusiran Data at EASL Congress 2024
May 22, 2024
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 2, 2024
Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
May 2, 2024
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
April 18, 2024
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
April 4, 2024
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
February 29, 2024
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
February 15, 2024
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
January 8, 2024
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®
November 9, 2023
Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 7, 2023
Arbutus Announces CEO, William Collier, to Retire December 31, 2023
November 7, 2023
Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update
October 24, 2023
Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference
October 18, 2023
Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023
October 11, 2023
Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended
September 11, 2023